Generics firms the ‘biggest cartel in US history’ – reportUS authorities looking into price fixing in the generics industry are now investigating 16 companies and the price Share XGenerics firms the ‘biggest cartel in US history’ – reporthttps://pharmaphorum.com/news/generics-firms-the-biggest-cartel-in-us-history-report/
Boehringer Ingelheim axes biosimilars development outside USBoehringer Ingelheim has said it has axed ex-US development of its biosimilars, focusing instead on getting its Humira Share XBoehringer Ingelheim axes biosimilars development outside UShttps://pharmaphorum.com/news/boehringer-ingelheim-axes-biosimilars-development-outside-us/
Open Health merges with med comms services provider PelotonUK-based Open Health Communications has merged with Peloton Advantage to create a global healthcare communications and market access Share XOpen Health merges with med comms services provider Pelotonhttps://pharmaphorum.com/news/open-health-merges-peloton-advantage/
New UK drug pricing deal promises faster medicines accessThe UK government has reached a new five-year medicines pricing deal with the pharma industry to replace the Share XNew UK drug pricing deal promises faster medicines accesshttps://pharmaphorum.com/news/new-uk-drug-pricing-deal-promises-faster-medicines-access/
Novartis/Spark’s sight gene therapy approved in EUSpark Therapeutics’ gene therapy for a rare inherited sight disorder, Luxturna has been approved in Europe, but there Share XNovartis/Spark’s sight gene therapy approved in EUhttps://pharmaphorum.com/news/novartis-sparks-sight-gene-therapy-approved-in-eu/
Late to the party but we brought friends: BeneLuxA’s horizon scanning initiativeIt can feel good to know what is coming your way; that’s no different for new medicines and Share XLate to the party but we brought friends: BeneLuxA’s horizon scanning initiativehttps://pharmaphorum.com/views-analysis-market-access/joint-horizon-scanning/
Pfizer to hike prices of 41 drugs despite Trump criticismPfizer plans to raise the prices of 41 prescription drugs in January, despite falling foul of President Trump, Share XPfizer to hike prices of 41 drugs despite Trump criticismhttps://pharmaphorum.com/news/pfizer-to-hike-prices-of-41-drugs-despite-trump-criticism/
Vertex told to reveal CF drug price, as MPs begin inquiryUK politicians could go public with the price of Vertex’s cystic fibrosis drug Orkambi, if the company does Share XVertex told to reveal CF drug price, as MPs begin inquiryhttps://pharmaphorum.com/news/vertex-told-to-reveal-cf-drug-price-as-mps-begin/
NICE rejects AZ’s Lynparza tablets in ovarian cancer maintenanceAstraZeneca has said it will continue pricing negotiations with the NHS and NICE after the cost-effectiveness body said Share XNICE rejects AZ’s Lynparza tablets in ovarian cancer maintenancehttps://pharmaphorum.com/news/nice-rejects-azs-lynparza-tablets-in-ovarian-cancer-maintenance/
